From private incentives to public health need : rethinking research and development for pandemic preparedness
Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved..
Pandemic preparedness and response have relied primarily on market dynamics to drive development and availability of new health products. Building on calls for transformation, we propose a new value proposition that instead prioritises equity from the research and development (R&D) stage and that strengthens capacity to control outbreaks when and where they occur. Key elements include regional R&D hubs free to adapt well established technology platforms, and independent clinical trials networks working with researchers, regulators, and health authorities to better study questions of comparative benefit and real-world efficacy. Realising these changes requires a shift in emphasis: from pandemic response to outbreak control, from one-size-fits-all economies of scale to R&D and manufacture for local need, from de novo product development to last-mile innovation through adaptation of existing technologies, and from proprietary, competitive R&D to open science and financing for the common good that supports collective management and sharing of technology and know-how.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
The Lancet. Global health - 11(2023), 10 vom: 30. Okt., Seite e1658-e1666 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Torreele, Els [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.09.2023 Date Revised 04.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2214-109X(23)00328-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361498942 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361498942 | ||
| 003 | DE-627 | ||
| 005 | 20231226085251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2214-109X(23)00328-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361498942 | ||
| 035 | |a (NLM)37652070 | ||
| 035 | |a (PII)S2214-109X(23)00328-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Torreele, Els |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a From private incentives to public health need |b rethinking research and development for pandemic preparedness |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2023 | ||
| 500 | |a Date Revised 04.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Pandemic preparedness and response have relied primarily on market dynamics to drive development and availability of new health products. Building on calls for transformation, we propose a new value proposition that instead prioritises equity from the research and development (R&D) stage and that strengthens capacity to control outbreaks when and where they occur. Key elements include regional R&D hubs free to adapt well established technology platforms, and independent clinical trials networks working with researchers, regulators, and health authorities to better study questions of comparative benefit and real-world efficacy. Realising these changes requires a shift in emphasis: from pandemic response to outbreak control, from one-size-fits-all economies of scale to R&D and manufacture for local need, from de novo product development to last-mile innovation through adaptation of existing technologies, and from proprietary, competitive R&D to open science and financing for the common good that supports collective management and sharing of technology and know-how | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Wolfe, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Kazatchkine, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Sall, Amadou |e verfasserin |4 aut | |
| 700 | 1 | |a Ruxrungtham, Kiat |e verfasserin |4 aut | |
| 700 | 1 | |a Fitchett, Joseph Robert Anderson |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Kobinger, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Vaca-González, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Terblanche, Petro |e verfasserin |4 aut | |
| 700 | 1 | |a Swaminathan, Soumya |e verfasserin |4 aut | |
| 700 | 1 | |a Olliaro, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Helen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Global health |d 2013 |g 11(2023), 10 vom: 30. Okt., Seite e1658-e1666 |w (DE-627)NLM237515954 |x 2214-109X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:10 |g day:30 |g month:10 |g pages:e1658-e1666 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2214-109X(23)00328-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 10 |b 30 |c 10 |h e1658-e1666 | ||